Back to Journals » ImmunoTargets and Therapy » Treating Comorbid Immune-Mediated Diseases with Immunotherapy
ImmunoTargets and Therapy
- View all (339)
- Volume 15, 2026 (37)
- Volume 14, 2025 (90)
- Volume 13, 2024 (56)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Journal Articles:
- Autoimmune Disease (4)
- The Role of Natural Killer Cells in Disease (1)
- Oral Vaccines for Infectious and or Non-Infectious Diseases (1)
- Modern diagnosis of autoimmune diseases (1)
Treating Comorbid Immune-Mediated Diseases with Immunotherapy
Patients with comorbid immune-mediated diseases have at least two or more autoimmune, allergic, infectious or inflammatory diseases that significantly impact their quality of life. Some conditions typically co-occur together, such as Sjogren’s Syndrome and Systemic Lupus Erythematosus. Other diseases may be a result of shared inflammatory signaling pathways or caused by the primary immune-mediated disease. Treating patients with comorbid immune-mediated diseases presents a unique challenge, as treatment may require a multidrug regimen with multiple opportunities for drug interaction.